



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 20 May 2019 (#16)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices & News

- [New FAQs](#) for NIH-MRC U.S.-South Africa Collaborative Research
- [Questions and Answers](#) for NIH's HIV/AIDS Clinical Trials Units (CTU) FOA, [RFA-AI-19-045](#)
- [TIPS: Letters of support](#) from your collaborators, key personnel, institution, and other significant contributors should demonstrate their commitment and summarize the agreements you have in place to support your project. Familiarize yourself with the recommendations given in the [SF 424 instructions on Letters of Support](#)
- Why is the [budget in my Notice of Award different](#) from what I requested in my application?
- [Guidance on Posting Informed Consent Forms for NIH-Funded Clinical Trials](#) (NOT-OD-19-110). This notice is to provide guidance to the NIH extramural research community regarding where to post clinical trial informed consent forms, as required by [Section 46.116\(h\)](#) of the Revised Common Rule (Subpart A of [45 CFR 46](#)).
- [NIGMS-Managed HIV/AIDS Research Portfolio Transitioning to NIAID](#) (NOT-GM-19-039). Effective immediately, the National Institute of General Medical Sciences (NIGMS) is transferring its HIV/AIDS portfolio, and all associated funds, to the National Institute of Allergy and Infectious Diseases (NIAID).
- [Notice of Special Interest: Alternatives to the Use of Human Fetal Tissues in NICHD-supported Research](#) (NOT-HD-19-011). Eunice Kennedy Shriver National Institute of Child Health and Human Development The NIH announced its intention to fund alternative approaches for modeling developmental processes that do not rely on the use of human fetal tissue obtained from pregnancy terminations ([NOT-OD-19-042](#)).

1. Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-19-030](#)

Type: U01

Application Due Date: July 22, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The objective of this Funding Opportunity Announcement (FOA) is to support the evaluation of early stage diagnostics and novel diagnostic strategies for Tuberculosis (TB) in the context of existing clinical algorithms in TB endemic countries. Evaluation studies should: 1) perform proof-of principle studies of novel diagnostic tests and strategies and 2) provide feedback to diagnostic developers on the performance of the technologies and most effective strategies for use of the diagnostic technologies in an endemic setting. Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. For this FOA, an "early-stage" diagnostic refers to one that has advanced to the stage where a prototype is ready and available to be evaluated but is not currently used in clinical care and treatment decisions for TB.

Budget: NIH intends to fund an estimate of 1-2 awards, corresponding to a total of \$4,000,000 for fiscal year 2020. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Provocative Questions (PQs) in Multiple Myeloma Disparities Research (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-279](#)

Type: R01

Application Due Date: November 15, 2019; July 15, 2020; November 15, 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites R01 applications for research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. The FOA includes six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project (application) proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen. The companion FOA, [PAR-19-280](#) is a parallel announcement for exploratory/developmental projects using the NIH R21 mechanism.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. NIAID Clinical Trial Planning Grant (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-281](#)

Type: R34

Application Due Date: September 13, 2019; January 13, 2020; May 12, 2020; September 14, 2020 January 12, 2021; May 14, 2021; September 13, 2021; January 14, 2022; May 13, 2022 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages applications that propose to complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high-priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (<https://www.niaid.nih.gov/research/role>).

Budget: Application budgets are limited to \$150,000 direct costs. The scope of the proposed project should determine the project period. The maximum period is one year.

4. Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-282](#)

Type: R61/R33

Application Due Date: October 10, 2019; July 10, 2020; March 10, 2021; October 13, 2021. Aids dates: January 7, 2020; September 7, 2020; May 7, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD), including fundamental brain function relevant to substance use. For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding mechanism (e.g., [Neuroscience Research on Drug Abuse \(R01 Clinical Trial Optional\)](#)).

Budget: For the R61 planning phase, the combined budget for direct costs for up to two years may not exceed \$500,000. For the R33 phase, budgets may exceed \$500,000. Applicants requesting \$500,000 or more in direct costs during the R33 phase in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application, as specified in Section IV.7). The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. The scope of the proposed project should determine the requested project period.

5. Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-283](#)

Type: D43

Application Due Date: August 20, 2019; August 20, 2020; August 20, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for research training programs to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research relevant to the evolving HIV epidemic in their country. This FOA can support training for conducting research in a broad range of HIV research areas across HIV prevention, treatment, care, and quality of life continuum. This includes basic, epidemiologic, clinical, behavioral and social sciences, community-based, implementation, operations, health services, and health systems research. Cross-disciplinary research as well as HIV associated comorbidities and coinfections affecting the HIV epidemic will be supported under this FOA. An application should focus the proposed training program to strengthen research capacity in a defined HIV scientific area at a specific LMIC institution and collaborating LMIC partner institutions. This FOA allows qualified Trainees to serve as the lead investigator of an independent clinical trial; or to propose a separate ancillary study to an existing trial under the mentorship of an appropriate clinical researcher or to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Budget: Application budgets are limited to \$280,000 in direct costs per year exclusive of consortium indirect costs. The maximum project period is 5 years.

6. Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-284](#)

Type: D71

Application Due Date: Only accepting applications for the AIDS Application Due Date(s). August 20, 2019; August 20, 2020; August 20, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The Fogarty HIV Research Training Program supports research training that strengthens HIV research capacity of institutions in low-and middle-income countries (LMICs). This FOA offers an opportunity for LMIC institutions to submit a planning grant application to prepare to participate in the Fogarty HIV Research Training Program.

These applications must propose a plan to develop a research training program and the subsequent application that will be submitted in response to the companion D43 FOA ([PAR-19-283](#)). The planned research training program should strengthen research capacity in a defined high priority HIV scientific area ([NOT-OD-15-137](#)) at an LMIC institution(s).

Budget: Application budgets are limited to \$28,000 direct costs per year exclusive of consortium indirect costs. The maximum project period is 2 years.

7. Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-285](#)

Type: G11

Application Due Date: August 20 2019, August 20, 2020, August 20, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The overall goal of the Fogarty HIV Research Training Program (HIVRT) is to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research on the evolving HIV epidemic in their countries. This Funding Opportunity Announcement (FOA) encourages collaborative applications from U.S. and LMIC institutions to develop training programs to achieve technical, administrative and financial management expertise required for one of several research infrastructure support functions considered critical to a successful high-quality research environment. These are: a) research administration and management, b) research integrity oversight, c) ethical review of research for the protection of human subjects, d) laboratory animal welfare oversight, e) health sciences library and information services, f) information and communications technology systems (ICT) for research, g) biostatistics and data analysis, h) technology transfer and intellectual property protection, and i) any area not mentioned above that justifiably will contribute to enhancing Institutional services that can support research activities. Research infrastructure support training programs will maximize previous investments, further strengthen the LMIC institution's research capabilities, and provide more accessible research infrastructure training opportunities to others in their own country and in other LMICs.

Budget: Application budgets are limited to \$94,000 direct costs per year exclusive of consortium indirect costs. The maximum project period is 3 years.

8. PrEP for HIV Prevention among Substance Using Populations (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-20-013](#)

Type: R01

Application Due Date: November 8, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: National Institute on Drug Abuse (NIDA) is interested in research that addresses research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. Only one clinical trial has evaluated PrEP among PWID and systematic data regarding the broader use of PrEP among substance users are limited. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. More systematic data are needed regarding the impact of substance use on PrEP management and adherence, along with investigating potential unintended consequences of PrEP use that may be unique to substance users such as changes in harm reduction practices, as well as substance use as a contributor to health risk behaviors with consequences such as increased occurrence of STIs.

Budget: NIDA intends to commit \$2,000,000 in FY 2020 to fund approximately 3 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105